CEUS/CT/MRI对肝细胞癌的现场诊断能力(2019-2022):一项多中心研究
该多中心研究纳入2019年5月至2022年4月共2085例患者2320个病理确诊的局灶性肝脏病变,比较CEUS、增强CT和增强MRI对HCC的现场诊断性能。三种影像在区分HCC与16种局灶性肝脏病变(包括≤2.0 cm的HCC)方面诊断性能相似;在低容量医院和高危因素HCC中,CEUS的敏感度低于增强MRI,但CEUS联合增强CT或增强MRI可提高诊断准确率。
要点
- CEUS在区分HCC与16种局灶性肝脏病变(含≤2.0 cm HCC)方面与增强CT、增强MRI诊断性能相似。
- 低容量医院及高危因素HCC中,CEUS敏感度低于增强MRI,但准确率和特异度与增强CT、增强MRI相当。
- CEUS联合增强CT或增强MRI较任一单独技术可提高HCC诊断准确率。
核心结论
- 与增强CT和增强MRI相比,CEUS在高容量医院的临床一线应用中提供足够的诊断性能;CEUS联合增强CT或增强MRI较任一单独影像技术可获得更高的HCC诊断性能。
研究设计与样本
- 多中心研究,纳入2019年5月至2022年4月共2085例患者2320个病理确诊的局灶性肝脏病变,将影像报告与病理分析结果进行比较,并按病变大小、HCC高危因素和医院容量类别分析诊断性能。
诊断标准与关键数值
- 三种影像在区分HCC与16种局灶性肝脏病变(包括HCC ≤2.0 cm)方面诊断性能相似。
- 低容量医院HCC中,CEUS敏感度77.4%,低于增强MRI的87.0%。
- 高危因素HCC中,CEUS敏感度89.5%,低于增强MRI的92.8%。
- HCC ≤2.0 cm中,CEUS+增强MRI和CEUS+增强CT的诊断准确率较增强MRI/增强CT单独分别提高7.8%和6.2%。
- 高危因素HCC中,CEUS+增强MRI和CEUS+增强CT的诊断准确率较增强MRI/增强CT单独分别提高8.0%和5.0%。
临床应用与阅片要点
- 在高容量医院临床一线应用中,CEUS对HCC可提供足够的诊断性能。
- 低容量医院HCC及高危因素HCC中,CEUS敏感度低于增强MRI,但准确率和特异度与增强CT、增强MRI相当。
- CEUS联合增强CT或增强MRI较任一单独影像技术可提高HCC诊断准确率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare the on-site diagnostic performance of contrast-enhanced ultrasound (CEUS), computed tomography (CECT), and magnetic resonance imaging (CEMRI) for hepatocellular carcinoma (HCC) across diverse practice settings.
METHODS: Between May 2019 and April 2022, a total of 2085 patients with 2320 pathologically confirmed focal liver lesions (FLLs) were enrolled. Imaging reports were compared with results from pathology analysis. Diagnostic performance was analyzed in defined size, high-risk factors for HCC, and hospital volume categories.
RESULTS: Three images achieved similar diagnostic performance in classifying HCC from 16 types of FLLs, including HCC ≤2.0 cm. For HCC diagnosis at low-volume hospitals and HCC with high-risk factors, the accuracy and specificity of CEUS were comparable to CECT and CEMRI, while the sensitivity of CEUS (77.4 and 89.5%, respectively) was inferior to CEMRI (87.0 and 92.8%, respectively). The diagnostic accuracy of CEUS + CEMRI and CEUS + CECT increased by 7.8 and 6.2% for HCC ≤2.0 cm, 8.0 and 5.0% for HCC with high-risk factors, and 7.4 and 5.5% for HCC at low-volume hospitals, respectively, compared with CEMRI/CECT alone.
CONCLUSIONS: Compared with CECT and CEMRI, CEUS provides adequate diagnostic performance in clinical first-line applications at high-volume hospitals. Moreover, a higher diagnostic performance for HCC is achieved by combining CEUS with CECT/CEMRI compared with any single imaging technique.
引用
- Yang Q, Zheng R, Zhou J, et al. On-Site Diagnostic Ability of CEUS/CT/MRI for Hepatocellular Carcinoma (2019-2022): A Multicenter Study. J Ultrasound Med. 2023. PMID: 37713625. doi:10.1002/jum.16321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。